The global pharmaceutical late-stage pipeline is the most valuable and most closely scrutinized asset base in any industry. Phase 3 clinical programs collectively represent hundreds of billions of dollars in potential future revenues. The pipeline across the ten leading companies on this list is the deepest and most technologically diverse in pharmaceutical history. Eli Lilly’s pipeline includes orforglipron, retatrutide, imlunestrant, and lebrikizumab. AstraZeneca’s pipeline extends across more than 170 projects in clinical development. Merck’s post-Keytruda pipeline is the most strategically critical in the industry.
Topics Covered
• Pipeline Overview by Company
• Approval Probability Analysis
• Revenue Outlook by Asset
• Pipeline Gaps and Acquisition Imperatives
• First-in-Class vs. Fast-Follower Dynamics
• Pipeline Productivity Benchmarking
Table of Contents
1. Executive Summary
2. Landscape Overview
3. Pipeline Overview by Company
4. Approval Probability Analysis
5. Revenue Outlook by Asset
6. Pipeline Gaps and Acquisition Imperatives
7. First-in-Class vs. Fast-Follower Dynamics
8. Pipeline Productivity Benchmarking
9. Competitive Landscape
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Program and Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
BASF
Dow
Evonik
Covestro
LyondellBasell
Solvay
Clariant
Arkema
